Category Archives: New Jersey Stem Cells

Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) and Pieris Pharmaceuticals Inc. (NASDAQ:PIRS), both competing one another are Biotechnology companies. We will compare their profitability, analyst recommendations, risk, institutional ownership, dividends, earnings and valuation.

Earnings and Valuation

In table 1 we can see Brainstorm Cell Therapeutics Inc. and Pieris Pharmaceuticals Inc.s top-line revenue, earnings per share and valuation.

Profitability

Table 2 represents Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) and Pieris Pharmaceuticals Inc. (NASDAQ:PIRS)s return on equity, return on assets and net margins.

Volatility & Risk

A beta of 1.19 shows that Brainstorm Cell Therapeutics Inc. is 19.00% more volatile than Standard and Poors 500. Competitively, Pieris Pharmaceuticals Inc.s 21.00% volatility makes it more volatile than Standard and Poors 500, because of the 1.21 beta.

Liquidity

Brainstorm Cell Therapeutics Inc.s Current Ratio and Quick Ratio are 1 and 1 respectively. The Current Ratio and Quick Ratio of its competitor Pieris Pharmaceuticals Inc. are 3 and 3 respectively. Pieris Pharmaceuticals Inc. therefore has a better chance of paying off short and long-term obligations compared to Brainstorm Cell Therapeutics Inc.

Analyst Ratings

The Recommendations and Ratings for Brainstorm Cell Therapeutics Inc. and Pieris Pharmaceuticals Inc. are featured in the next table.

Brainstorm Cell Therapeutics Inc. has a consensus target price of $9, and a 140.00% upside potential. Competitively Pieris Pharmaceuticals Inc. has a consensus target price of $5, with potential upside of 45.77%. The data from earlier shows that analysts view suggest that Brainstorm Cell Therapeutics Inc. seems more appealing than Pieris Pharmaceuticals Inc.

Insider and Institutional Ownership

The shares of both Brainstorm Cell Therapeutics Inc. and Pieris Pharmaceuticals Inc. are owned by institutional investors at 11.4% and 61.7% respectively. About 0.6% of Brainstorm Cell Therapeutics Inc.s share are held by insiders. On the other hand, insiders held about 0.23% of Pieris Pharmaceuticals Inc.s shares.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

For the past year Brainstorm Cell Therapeutics Inc. has weaker performance than Pieris Pharmaceuticals Inc.

Summary

On 8 of the 11 factors Pieris Pharmaceuticals Inc. beats Brainstorm Cell Therapeutics Inc.

Brainstorm Cell Therapeutics Inc., a biotechnology company, develops adult stem cell therapies for neurodegenerative disorders that include amyotrophic lateral sclerosis, multiple sclerosis, Parkinsons disease, and others. The company holds rights to develop and commercialize its NurOwn technology through a licensing agreement with Ramot of Tel Aviv University Ltd. Its NurOwn technology is based on a novel differentiation protocol, which induces differentiation of the bone marrow-derived mesenchymal stem cells into neuron-supporting cells and secreting cells that release various neurotrophic factors, including glial-derived neurotrophic factor, brain-derived neurotrophic factor, vascular endothelial growth factor, and hepatocyte growth factor for the growth, survival, and differentiation of developing neurons. The company was formerly known as Golden Hand Resources Inc. and changed its name to Brainstorm Cell Therapeutics Inc. in November 2004 to reflect its new line of business in the development of novel cell therapies for neurodegenerative diseases. Brainstorm Cell Therapeutics Inc. was founded in 2000 and is headquartered in Hackensack, New Jersey.

Pieris Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, discovers and develops Anticalin-based drugs. It develops Anticalin proteins that are low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins found in blood plasma and other bodily fluids. The company primarily focuses on the development of four drug candidates, including PRS-080 designed to target hepcidin for the treatment of functional iron deficiency in anemic patients with chronic kidney disease or in end-stage renal disease patients requiring dialysis; PRS-060, a drug candidate that binds to the IL-4RA receptor alpha-chain, which is used for the treatment of asthma and other inflammatory diseases; PRS-343, a bispecific protein for oncology diseases; and PRS-332, a bispecific anticalin-antibody fusion protein for oncology diseases. It has strategic partnership agreements with Allergan, Inc.; Sanofi Group; Daiichi Sankyo Company Limited; F.Hoffmann- La Roche Ltd. and Hoffmann- La Roche Inc.; ASKA Pharmaceutical Co., Ltd; and Les Laboratoires Servier and Institut de Recherches Internationales. The company also has a research and licensing agreement with Technische Universitt Mnchen; and a collaboration agreement with AstraZeneca. Pieris Pharmaceuticals, Inc. is headquartered in Boston, Massachusetts.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Read more here:
Reviewing Brainstorm Cell Therapeutics Inc. (BCLI)'s and Pieris Pharmaceuticals Inc. (NASDAQ:PIRS)'s results - MS Wkly

This is therefore a contrasting of the analyst recommendations, profitability, risk, dividends, earnings and valuation, institutional ownership in ImmunoGen Inc. (NASDAQ:IMGN) and Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI). The two are both Biotechnology companies that compete with one another.

Valuation and Earnings

Table 1 demonstrates ImmunoGen Inc. and Brainstorm Cell Therapeutics Inc.s top-line revenue, earnings per share (EPS) and valuation.

Profitability

Table 2 demonstrates the return on assets, net margins and return on equity of ImmunoGen Inc. and Brainstorm Cell Therapeutics Inc.

Volatility & Risk

ImmunoGen Inc. has a 2.28 beta, while its volatility is 128.00%, thus making it more volatile than Standard & Poors 500. In other hand, Brainstorm Cell Therapeutics Inc. has beta of 1.19 which is 19.00% more volatile than Standard & Poors 500.

Liquidity

The Current Ratio of ImmunoGen Inc. is 4.7 while its Quick Ratio stands at 4.7. The Current Ratio of rival Brainstorm Cell Therapeutics Inc. is 1 and its Quick Ratio is has 1. ImmunoGen Inc. is better equipped to clear short and long-term obligations than Brainstorm Cell Therapeutics Inc.

Analyst Ratings

ImmunoGen Inc. and Brainstorm Cell Therapeutics Inc. Recommendations and Ratings are available in the next table.

Brainstorm Cell Therapeutics Inc. on the other hand boasts of a $9 average target price and a 140.64% potential upside.

Insider & Institutional Ownership

Roughly 80.3% of ImmunoGen Inc. shares are held by institutional investors while 11.4% of Brainstorm Cell Therapeutics Inc. are owned by institutional investors. Insiders held roughly 0.6% of ImmunoGen Inc.s shares. On the other hand, insiders held about 0.6% of Brainstorm Cell Therapeutics Inc.s shares.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

For the past year ImmunoGen Inc. had bearish trend while Brainstorm Cell Therapeutics Inc. had bullish trend.

ImmunoGen, Inc., a clinical-stage biotechnology company, develops targeted anticancer therapeutics. The company develops its products using its antibody-drug conjugate (ADC) technology. The companys product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha for the treatment of platinum-resistant ovarian cancer; IMGN529, an ADC that is in Phase 1b/2 clinical trials for B-cell malignancies; coltuximab ravtansine, which is in Phase 2 trials for B-cell malignancies; IMGN779 that is in Phase 1 clinical trials for the treatment of acute myeloid leukemia (AML); and IMGN632, a preclinical CD123-targeting ADC for the treatment of hematological malignancies, including AML. ImmunoGen, Inc. has collaborations with Roche; Bayer HealthCare AG; Sanofi; Biotest AG; Novartis Institutes for BioMedical Research, Inc.; Eli Lilly and Company; Amgen; Takeda Pharmaceutical Company Limited; Merck; and CytomX Therapeutics, Inc. ImmunoGen, Inc. was founded in 1981 and is headquartered in Waltham, Massachusetts.

Brainstorm Cell Therapeutics Inc., a biotechnology company, develops adult stem cell therapies for neurodegenerative disorders that include amyotrophic lateral sclerosis, multiple sclerosis, Parkinsons disease, and others. The company holds rights to develop and commercialize its NurOwn technology through a licensing agreement with Ramot of Tel Aviv University Ltd. Its NurOwn technology is based on a novel differentiation protocol, which induces differentiation of the bone marrow-derived mesenchymal stem cells into neuron-supporting cells and secreting cells that release various neurotrophic factors, including glial-derived neurotrophic factor, brain-derived neurotrophic factor, vascular endothelial growth factor, and hepatocyte growth factor for the growth, survival, and differentiation of developing neurons. The company was formerly known as Golden Hand Resources Inc. and changed its name to Brainstorm Cell Therapeutics Inc. in November 2004 to reflect its new line of business in the development of novel cell therapies for neurodegenerative diseases. Brainstorm Cell Therapeutics Inc. was founded in 2000 and is headquartered in Hackensack, New Jersey.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Original post:
Reviewing ImmunoGen Inc. (IMGN)'s and Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI)'s results - MS Wkly

By Denny Dyroff, Entertainment Editor, The Times

Allegaeon

Whenever Allegaeon comes to the area for a show, metal music fans get excited.

Allegaeon plays a smorgasbord of metal music that rattles the rafters and usually tours on a bill with several top-flight metal acts.

When Allegaeon played the Voltage Lounge last year, the band was on a bill that included Rings of Saturn, Entheos, Neckrogoblikon, Lorna Shore and Gloom.

On October 31, Allegaeon will bring its Apoptosis Tour Pt II to MilkBoy Philly (1100 Chestnut Street, Philadelphia, 215- 925-6455, http://www.milkboyphilly.com). The show will also include a trio of opening acts Paladin, Inferi and IATT.

The current line-up of Allegaeon features Greg Burgess, lead guitar (2008present); Michael Stancel, rhythm guitar (2013present); Brandon Park, drums (2013present); Riley McShane, vocals (2015present); and Brandon Michael, bass (2017present).

Allegaeon has released five albums Fragments of Form and Function (2010), Formshifter (2012), Elements of the Infinite (2104), Proponent for Sentience (2016), and Apoptosis (2109). All five are on Metal Blade Records.

Judging by the album titles, this is not a typical gloom metal band singing about anger-fueled rebellion, animal mutilation or the impending end of the world.

Allegaeon plays a wide variety of styles mostly within the realm of metal music. The band plays death metal and incorporates technical expertise and a sense of melody without sacrificing the heaviness inherent in death metal.

Listeners can hear many influences, including prog-rock, thrash metal, classical music and prog-metal. Lyrical themes are both heavy and intellectual stem cell research, alien life, evolution, physics, artificial intelligence, cryonic experimentation and biology.

Were a melodic death metal band that experiments with a lot of different genres and influences, said McShane, during a phone interview Monday afternoon. Theres something for everyone.

With Allegaeon, a lot of metal fans can find something to identify with. Our song structure is pretty straightforward. Technical fans also can find a lot to like. But the foundation is always death metal.

Apoptosis dropped in April and the band has been touring ever since.

We recorded the album in November and December last year, said McShane. We tracked at Flatline Audio in Denver with producer Dave Otero. Weve always worked with Dave. Hes a phenomenal engineer.

We approached the writing differently with this album. The writing was different because we were on the road. So, it was more organinc and less formulaic. Instead of trying to write an album, we just wrote.

The result was that the band wrote a powerful album with songs that fit together perfectly.

According to McShane, Thematically, this record is all about contrast, and the music reflects that perfectly. The vocals are heavier than ever, but there are also more clean sections. The drums are faster than ever but also more dynamic, and the guitar playing is lower and slower than on most previous albums, but also provides long, melodic and beautiful sections throughout.

Allegaeon got its start in northern Colorado in 2008.

Were still based out of Denver, said McShane I live in Escondido, California, our drummer lives in Illinois and our bassist lives in Northern California. But Denver remains our home base.

I was living in Santa Cruz and was in a band called Son of Aurelius and we had an album that was Gregs favorite album ever. Allegaeon needed a vocalist so Greg hit me up.

With every member change, the foundation of Allegaeons sound is kept intact but each new member brings something new to the table. I was really excited when Brandon Michael joined the band because he has such a versatile bass style.

The definition of the word, apoptosis, is the death of cells which occurs as a normal and controlled part of an organisms growth or development.

Our album Apoptosis is all about new cells replacing old cells, said McShane. Its the idea of the old with the new. Its about how weve grown over the years. There are also lyrical themes of science like weve always used.

We took the music in a heavier direction but also in a more melodic direction while maintaining the same strengths weve always had.

But you have to be careful. You cant take to many hard-left turns. You dont want to lose old fans, and, at the same time, you dont want to make the same album over and over again.

But, like I said, the foundation is always death metal melodic and technical. I dont think that will ever change.

Video link for Allegaeon https://youtu.be/UfwkhX803JI?list=PL287EF95A4FFE743F.

Paladin

Paladin, which is billed as a power metal band, is a hard-hitting quartet featuring Taylor Washington, Guitar/Vocals; Alex Parra, Guitar; Andy McGraw, Bass/Vocals; and Nathan McKinney, Drums.

The band, which formed in 2015 in Atlanta, just released its debut album, Ascension, a few months ago on Prosthetic Records.

Ascension immediately entered the U.S. Billboard charts upon its May 17 release at the following positions Billboard Hard Music Albums #35; BillboardTop New Artists Album #40; BillboardIndependent Albums #88; and Billboard Digital Albums #182.Incorporating an array of influences from 1980s metal to melodic death metal into its blend of power thrash, Paladin is on a mission to bring some European flavor to the US metal scene with Ascension.

This is our first tour in support of the album and our first real tour in general, said Washington, during a phone interview Monday from a tour stop in Orlando, Florida. We went on a short run in August. And, we played ProgPower this year.

ProgPower USA is a progressive, power metal, and progressive rock festival held annually in the United States since 2001. Its most recent edition, ProgPower USA XX, was held at Center Stage in Atlanta, Georgia from September 4-7, 2019. Paladin is now on a 17-day nationwide tour.

We recorded Ascension at Matt Smith at Theocracized Studios in Athens, Georgia. The studio belongs to Matt Smith, who is in a band called Theocracy. We co-produced the album with Matt and then he mixed and mastered it.

Matt, who is Theocracys vocalist, plays keyboards and guitar. He is a great producer and a great musician. And his style of music is similar to ours.

Paladin has its roots in Atlanta in 2015 when Washington and Parra were looking for a new vehicle for their music.

Paladin came from the ashes of another band in Atlanta, said Washington. I was playing guitar and Alex was playing bass in a metal band called Sybaritic.

That band broke up and some of us kept going as Paladin. I started doing vocals and Alex switched to guitar. That was four-and-a-half years ago. Weve gone through two lineup changes since then. Nate has now been our drummer for four years and we have a new bass player.

Paladin now has a stable line-up and a well-received new album.

Certain thematic elements run through the album, said Washington. There is the theme of duality light vs. darkgood vs. evil. There is also a running theme of positivity and perseverance.

Video link for Paladin https://youtu.be/U_X2L2ixbXA.

The show at MilkBoy Philly, which features Allegaeon, Paladin, Inferi and IATT, will start at 7:30 p.m. Tickets are $18.

Othr upcoming shows at MilkBoy Philly are American Dinosaur and Sun Parade on November 1, Adam Flymo Birch and the Vershions on November 2, Funk You on November 3, Ida Mae on November 4, JJ Wilde on November 5, and Blockhead on November 6.

Huntertones

Huntertones is a high energy horn-driven group founded in Columbus, Ohio and currently based in Brooklyn, New York. On October 31, Huntertones will be sharing the bill with Great Time at World Caf Live (3025 Walnut Street, Philadelphia, 215-222-1400, http://www.worldcafelive.com).

The bands signature sound is a marriage of inspired improvisation and adventurous compositions that meld jazz, funk, soul, hip-hop, R&B, and rock. In addition to covering a wide range of genres, the versatile group is known for the ability to shift from a dynamic six-piece ensemble to an unconventional trio featuring saxophone, sousaphone, and beat-boxing.

The current Huntertones line-up features Dan White, Saxophones; Jon Lampley, Trumpet/Sousaphone; Chris Ott, Trombone/Beatbox; Josh Hill, Guitar; John Hubbell, Drums; and Adam DeAscentis, Bass.

We tour the states pretty regularly festivals, rock rooms, jazz clubs, said White, during a phone interview last week from his home in Brooklyn.

When Huntertones play shows in Michigan, a bit of caution is needed on the part of the band.

The biggest and most intense rivalry in major college football is the one between the University of Michigan and The Ohio State University. The Philadelphia Eagles-Dallas Cowboys rivalry pales in comparison.

The members of Huntertones met at The Ohio State University and got their start playing house shows at their Hunter Avenue apartment.

Chris and Jon were both in The Ohio State University Marching Band, said White.

This fall, we collaborated with The Ohio State University Marching Band. They played one of our songs in their show. It was a tribute to our song Togo, which is on our latest album.

Were all very aware of the intensity of the rivalry between the two schools. When we were still in Columbus, if we had shows in Michigan, wed just say that we were a band from Ohio. If we were playing Ann Arbor, we definitely didnt want to bring up our connection to Ohio State. Now, weve been living in Brooklyn for five years.

The band started 2016 with a month-long tour of North America, South America, and Africa through the American Music Abroad program. They were selected by the U.S. Department of State and the Bureau of Educational and Cultural Affairs to engage international audiences, students, and artists from around the globe.

When we moved to New York, we hooked up with American Music Abroad, said White. One of our first countries was Togo. Weve done three tours with them altogether and we have another coming up this January. On our own, weve toured Japan, China and South Korea. And, weve spent the last two summers touring Europe.

Considering all the travel Huntertones has done, it made sense to call the new album, Passport.

All the international touring was inspiration for our latest album, said White, who is a native of Buffalo, New York. We picked up stylistic influences coming from different places. We were also influenced by the stories.

We recorded Passport in Jersey City at Kaleidoscope Sound. It has a nice big main room and that allowed us to play together live in one space. We recorded it December 2017 and released it last fall.

Were releasing a new single on November 8 called Disco Tent. We recorded the track when we were out on tour. Well be going into the studio to record our next album soon.

Video link for Huntertones https://youtu.be/KRu6wugevy0.

The show at the World Caf Live, which also features Great Time, will start at 8 p.m. Tickets are $12.

Other upcoming shows at the venue are The John Byrne Band Album Release Show on November 1, Superchunk on November 5 and Brendan James on November 6.

Come from Away

Now through November 3, the hit musical Come from Away is being presented at the Academy of Music (Broad and Locust streets, Philadelphia, 215-731-3333,www.kimmelcenter.org) as part of the Kimmel Centers Broadway Philadelphia series.

The musical Come from Away is the uplifting and true story of 7,000 stranded passengers and the people of Gander, Newfoundland, the small Canadian town that welcomed them. Cultures clashed and nerves ran high, but uneasiness turned into trust, music soared into the night, and gratitude grew into enduring friendships.

It is set in the week following the September 11 attacks and tells the true story of what transpired when 38 planes were ordered to land unexpectedly in the small town of Gander in the province of Newfoundland and Labrador, Canada, as part of Operation Yellow Ribbon.

The characters in the musical are based on (and in most cases share the names of) real Gander residents as well as some of the thousands of stranded travelers they housed and fed.

The music in the show is a marriage of history and culture in Newfoundland. Its also married to a traditional Broadway sound.

Video link for Come from Away https://youtu.be/Nwm1IVAbnXk.

Come from Away is running now through November 3 at the Academy of Music. Ticket prices range from $20-$139.

Vassal

Kennett Flash (102 Sycamore Alley, Kennett Square, 484-732-8295,http://www.kennettflash.org) will have LENNON LIVE A Tribute to John Lennon on November 1 and Open Mic with Vassal on November 3.

The Steel City Coffee House (203 Bridge Street, Phoenixville, 610-933-4043, http://www.steelcitycoffeehouse.com) will host The Beatles Breadbasket on November 1 and Rofo Audio with Roi and the Secret People on November 2.

Chaplins (66 North Main Street, Spring City, 610-792-4110,http://chaplinslive.com) will host Haxon, Pandemic, Relapsed, and Tachyon on November 1 and Steve Zinno, Nick Filone, and Ralph Pagano on November 2.

Living Room (35 East Lancaster Avenue, Ardmore, https://thelivingroomat35east.com) will host Hot Club of Philadelphia on November 1 and The Peace Creeps on November 2.

The Ardmore Music Hall (23 East Lancaster Avenue, Ardmore, 610-649-8389,www.ardmoremusic.com) will present Splintered Sunlight on October 31, Philly Bloco on November 1, Aztec Two Step on November 2, Live Dead 69 featuring Tom Constanten plus members of Ratdog, Jefferson Starship on November 3, and Trigger Hippy on November 6.

Burlap & Bean Coffeehouse (204 South Newtown Street Road, Newtown Square, 484-427-4547,www.burlapandbean.com) will host Vilebred on November 1.

118 North (118 North Wayne Avenue, Wayne, http://www.118northwayne.com) will host Atlas Gray on November 1 and Dead Friends on November 2.

The Locks at Sona (4417 Main Street, Manayunk, 484- 273-0481, sonapub.com) will have Joseph Arthur on November 1, and Susan Werner with special guest Vanida Gail on November 2 and 3.

The Keswick Theater (291 N. Keswick Avenue, Glenside, 215-572-7650,www.keswicktheatre.com) presents The Hooters on November 1 and 2 and Home Free on November 6.

Annenberg Center (3680 Walnut Street, Philadelphia, https://annenbergcenter.org/events) will present Vox Luminis on November 1.

The Sellersville Theater (24 West Temple Avenue, Sellersville, 215-257-5808,www.st94.com) will have Swing That Cat on October 31, Tom Cotter on November 1, Marcia Ball on November 2, Arrival from Sweden: Music of Abba on November 3, Adrian Legg & Laurence Juber on November 4, All Star Tribute to the Flying Burrito Brothers on November 5, and The Outlaws on November 6.

The Grand Opera House (818 North Market Street, Wilmington, Delaware, 302-652-5577, http://www.thegrandwilmington.org) will present Home Free on November 1.

Read this article:
On Stage: Allegaeon ready to rock Philly - The Unionville Times

Merus N.V. (NASDAQ:MRUS) and Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) compete with each other in the Biotechnology sector. We will analyze and contrast their profitability, analyst recommendations, institutional ownership, risk, dividends, earnings and valuation.

Earnings & Valuation

Table 1 shows the top-line revenue, earnings per share and valuation for Merus N.V. and Brainstorm Cell Therapeutics Inc.

Profitability

Table 2 shows the return on equity, net margins and return on assets of the two firms.

Liquidity

Merus N.V.s Current Ratio and Quick Ratio are 6.4 and 6.4 respectively. The Current Ratio and Quick Ratio of its competitor Brainstorm Cell Therapeutics Inc. are 1 and 1 respectively. Merus N.V. therefore has a better chance of paying off short and long-term obligations compared to Brainstorm Cell Therapeutics Inc.

Analyst Ratings

The next table highlights the shown recommendations and ratings for Merus N.V. and Brainstorm Cell Therapeutics Inc.

Merus N.V.s upside potential currently stands at 37.03% and an $22.5 average price target.

Insider and Institutional Ownership

The shares of both Merus N.V. and Brainstorm Cell Therapeutics Inc. are owned by institutional investors at 65.8% and 11.4% respectively. Merus N.V.s share held by insiders are 30.47%. Comparatively, 0.6% are Brainstorm Cell Therapeutics Inc.s share held by insiders.

Performance

In this table we show the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

For the past year Merus N.V.s stock price has smaller growth than Brainstorm Cell Therapeutics Inc.

Merus N.V., a clinical-stage immuno-oncology company, engages in developing bispecific antibody therapeutics. Its lead bispecific antibody candidate is MCLA-128, which is in Phase I/II clinical trials in Europe for the treatment of various solid tumors, including breast, gastric, and ovarian cancers. The company also develops MCLA-117, a bispecific antibody candidate that is expected to commence a Phase I/II clinical trial for the treatment of patients with acute myeloid leukemia, as well as for the treatment of myelodysplastic syndrome in pre-clinical studies, as well as developing MCLA-158, a bispecific antibody candidate, which is designed to bind to cancer stem cells for the potential treatment of colorectal cancer. Its pre-clinical bispecific antibody candidates include MCLA-134 and MCLA-145, as well as other early research projects. The company has a strategic collaboration with Incyte and ONO Pharmaceutical Co., Ltd. to develop bispecific antibody candidates based on Biclonics technology platform. Merus N.V. was founded in 2003 and is headquartered in Utrecht, the Netherlands.

Brainstorm Cell Therapeutics Inc., a biotechnology company, develops adult stem cell therapies for neurodegenerative disorders that include amyotrophic lateral sclerosis, multiple sclerosis, Parkinsons disease, and others. The company holds rights to develop and commercialize its NurOwn technology through a licensing agreement with Ramot of Tel Aviv University Ltd. Its NurOwn technology is based on a novel differentiation protocol, which induces differentiation of the bone marrow-derived mesenchymal stem cells into neuron-supporting cells and secreting cells that release various neurotrophic factors, including glial-derived neurotrophic factor, brain-derived neurotrophic factor, vascular endothelial growth factor, and hepatocyte growth factor for the growth, survival, and differentiation of developing neurons. The company was formerly known as Golden Hand Resources Inc. and changed its name to Brainstorm Cell Therapeutics Inc. in November 2004 to reflect its new line of business in the development of novel cell therapies for neurodegenerative diseases. Brainstorm Cell Therapeutics Inc. was founded in 2000 and is headquartered in Hackensack, New Jersey.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Read the original:
Comparison of Merus N.V. (MRUS) and Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) - MS Wkly

As Biotechnology companies, NewLink Genetics Corporation (NASDAQ:NLNK) and Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) are our subject to contrast. And more specifically their analyst recommendations, profitability, risk, dividends, institutional ownership, earnings and valuation.

Earnings and Valuation

Table 1 showcases the top-line revenue, earnings per share and valuation of NewLink Genetics Corporation and Brainstorm Cell Therapeutics Inc.

Profitability

Table 2 shows us NewLink Genetics Corporation and Brainstorm Cell Therapeutics Inc.s net margins, return on equity and return on assets.

Volatility & Risk

NewLink Genetics Corporations current beta is 1.31 and it happens to be 31.00% more volatile than Standard and Poors 500. Competitively, Brainstorm Cell Therapeutics Inc.s 19.00% volatility makes it more volatile than Standard and Poors 500, because of the 1.19 beta.

Liquidity

The current Quick Ratio of NewLink Genetics Corporation is 13.3 while its Current Ratio is 13.3. Meanwhile, Brainstorm Cell Therapeutics Inc. has a Current Ratio of 1 while its Quick Ratio is 1. NewLink Genetics Corporation is better positioned to pay off its short-term and long-term debts than Brainstorm Cell Therapeutics Inc.

Institutional and Insider Ownership

NewLink Genetics Corporation and Brainstorm Cell Therapeutics Inc. has shares held by institutional investors as follows: 34.6% and 11.4%. 0.1% are NewLink Genetics Corporations share held by insiders. On the other hand, insiders held about 0.6% of Brainstorm Cell Therapeutics Inc.s shares.

Performance

In this table we show the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

For the past year NewLink Genetics Corporation has stronger performance than Brainstorm Cell Therapeutics Inc.

Summary

NewLink Genetics Corporation beats on 7 of the 10 factors Brainstorm Cell Therapeutics Inc.

NewLink Genetics Corporation, a biopharmaceutical company, focuses on discovering, developing, and commercializing immunotherapeutic products for the treatment of cancer. Its portfolio includes biologic product candidates based on its HyperAcute cellular immunotherapy technology, which is designed to stimulate the human immune system to attack cancer cells; and small-molecule product candidates that are focused on breaking the immune system's tolerance to cancer by inhibiting the indoleamine-2, 3-dioxygenase pathway and the tryptophan-2, 3-dioxygenase pathway. The company is developing IDO pathway inhibitors comprising indoximod that is in multiple Phase I and Phase II clinical trials for patients with melanoma, pancreatic cancer, malignant brain tumors, metastatic breast cancer, acute myeloid leukemia, prostate cancer, and non-small cell lung cancer (NSCLC); and GDC-0919 and atezolizumab (MPDL3280A) that is in Phase Ib clinical trials for patients with locally advanced or metastatic solid tumors. Its clinical development products include NLG2101 for metastatic breast cancer; NLG2102 for refractory malignant brain tumors; NLG2103 for advanced melanoma; NLG2104 for metastatic pancreatic cancer; NLG2105 for pediatric patients with refractory malignant brain tumors; and NLG2106 for acute myelogenous leukemia. The companys HyperAcute cellular immunotherapy product candidates under clinical development include tergenpumatucel-L, is being investigated in Phase Ib/II clinical trial for patients with advanced NSCLC; and dorgenmeltucel-L, is being investigated in a Phase II clinical trial for patients with advanced melanoma. Its infectious disease program includes replication-competent recombinant vesicular stomatitis virus, a vaccine technology to treat Ebola and Marburg viruses. The company has license and collaboration agreements with Genentech, Inc. and Merck, Sharpe and Dohme Corp. NewLink Genetics Corporation was founded in 1999 and is headquartered in Ames, Iowa.

Brainstorm Cell Therapeutics Inc., a biotechnology company, develops adult stem cell therapies for neurodegenerative disorders that include amyotrophic lateral sclerosis, multiple sclerosis, Parkinsons disease, and others. The company holds rights to develop and commercialize its NurOwn technology through a licensing agreement with Ramot of Tel Aviv University Ltd. Its NurOwn technology is based on a novel differentiation protocol, which induces differentiation of the bone marrow-derived mesenchymal stem cells into neuron-supporting cells and secreting cells that release various neurotrophic factors, including glial-derived neurotrophic factor, brain-derived neurotrophic factor, vascular endothelial growth factor, and hepatocyte growth factor for the growth, survival, and differentiation of developing neurons. The company was formerly known as Golden Hand Resources Inc. and changed its name to Brainstorm Cell Therapeutics Inc. in November 2004 to reflect its new line of business in the development of novel cell therapies for neurodegenerative diseases. Brainstorm Cell Therapeutics Inc. was founded in 2000 and is headquartered in Hackensack, New Jersey.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

See more here:
Comparing of NewLink Genetics Corporation (NLNK) and Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) - MS Wkly

This is therefore a contrasting of the risk, analyst recommendations, profitability, dividends, earnings and valuation, institutional ownership in Curis Inc. (NASDAQ:CRIS) and Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI). The two are both Biotechnology companies that compete with one another.

Valuation and Earnings

Table 1 demonstrates Curis Inc. and Brainstorm Cell Therapeutics Inc.s top-line revenue, earnings per share (EPS) and valuation.

Profitability

Table 2 shows us Curis Inc. and Brainstorm Cell Therapeutics Inc.s return on assets, return on equity and net margins.

Risk and Volatility

A 2.47 beta means Curis Inc.s volatility is 147.00% more than Standard and Poors 500s volatility. Brainstorm Cell Therapeutics Inc.s 1.19 beta is the reason why it is 19.00% more volatile than Standard and Poors 500.

Liquidity

The Current Ratio and a Quick Ratio of Curis Inc. are 9.8 and 9.8. Competitively, Brainstorm Cell Therapeutics Inc. has 1 and 1 for Current and Quick Ratio. Curis Inc.s better ability to pay short and long-term obligations than Brainstorm Cell Therapeutics Inc.

Institutional & Insider Ownership

Institutional investors held 24.7% of Curis Inc. shares and 11.4% of Brainstorm Cell Therapeutics Inc. shares. 17.28% are Curis Inc.s share held by insiders. Insiders Comparatively, held 0.6% of Brainstorm Cell Therapeutics Inc. shares.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

For the past year Curis Inc. was more bullish than Brainstorm Cell Therapeutics Inc.

Summary

Curis Inc. beats on 7 of the 9 factors Brainstorm Cell Therapeutics Inc.

Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. The company develops CUDC-907, an oral small molecule inhibitor of histone deacetylase and phosphatidylinositol-3-kinase enzymes, which is in Phase II clinical trials for relapsed or refractory diffuse large B-cell lymphoma, as well as in Phase I clinical trials for patients with solid tumors; CA-170, an oral small molecule drug candidate that is in Phase I clinical trials in patients with advanced solid tumors and lymphomas; CA-4948, an oral small molecule drug candidate, which is in preclinical stage for the treatment of hematologic cancers; and CA-327, an oral small molecule drug candidate that is in preclinical stage for the treatment of cancers. It is also developing Erivedge, an orally-administered small molecule hedgehog pathway inhibitor for advanced basal cell carcinoma, idiopathic pulmonary fibrosis, and myelofibrosis. The company has collaboration agreement with Aurigene Discovery Technologies Limited for the discovery, development, and commercialization of small molecule compounds in the areas of immuno-oncology and precision oncology; and collaboration and license agreement with F. Hoffmann-La Roche Ltd. and Genentech Inc. for the development and commercialization of Erivedge. Curis, Inc. was founded in 2000 and is headquartered in Lexington, Massachusetts.

Brainstorm Cell Therapeutics Inc., a biotechnology company, develops adult stem cell therapies for neurodegenerative disorders that include amyotrophic lateral sclerosis, multiple sclerosis, Parkinsons disease, and others. The company holds rights to develop and commercialize its NurOwn technology through a licensing agreement with Ramot of Tel Aviv University Ltd. Its NurOwn technology is based on a novel differentiation protocol, which induces differentiation of the bone marrow-derived mesenchymal stem cells into neuron-supporting cells and secreting cells that release various neurotrophic factors, including glial-derived neurotrophic factor, brain-derived neurotrophic factor, vascular endothelial growth factor, and hepatocyte growth factor for the growth, survival, and differentiation of developing neurons. The company was formerly known as Golden Hand Resources Inc. and changed its name to Brainstorm Cell Therapeutics Inc. in November 2004 to reflect its new line of business in the development of novel cell therapies for neurodegenerative diseases. Brainstorm Cell Therapeutics Inc. was founded in 2000 and is headquartered in Hackensack, New Jersey.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Read the original here:
Reviewing Curis Inc. (CRIS)'s and Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI)'s results - MS Wkly

Morphic Holding Inc. (NASDAQ:MORF) and Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI), both competing one another are Biotechnology companies. We will compare their risk, analyst recommendations, profitability, dividends, institutional ownership, earnings and valuation.

Valuation & Earnings

We can see in table 1 the earnings per share (EPS), top-line revenue and valuation of Morphic Holding Inc. and Brainstorm Cell Therapeutics Inc.

Profitability

Table 2 shows us the return on equity, return on assets and net margins of both businesses.

Liquidity

The current Quick Ratio of Morphic Holding Inc. is 4.6 while its Current Ratio is 4.6. Meanwhile, Brainstorm Cell Therapeutics Inc. has a Current Ratio of 1 while its Quick Ratio is 1. Morphic Holding Inc. is better positioned to pay off its short-term and long-term debts than Brainstorm Cell Therapeutics Inc.

Analyst Recommendations

In next table is given Morphic Holding Inc. and Brainstorm Cell Therapeutics Inc.s ratings and recommendations.

The average price target of Morphic Holding Inc. is $32, with potential upside of 134.78%.

Institutional & Insider Ownership

Morphic Holding Inc. and Brainstorm Cell Therapeutics Inc. has shares held by institutional investors as follows: 49.9% and 11.4%. Insiders held roughly 26.4% of Morphic Holding Inc.s shares. Comparatively, Brainstorm Cell Therapeutics Inc. has 0.6% of its share held by insiders.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

For the past year Morphic Holding Inc.s stock price has bigger growth than Brainstorm Cell Therapeutics Inc.

Summary

Morphic Holding Inc. beats Brainstorm Cell Therapeutics Inc. on 6 of the 8 factors.

Brainstorm Cell Therapeutics Inc., a biotechnology company, develops adult stem cell therapies for neurodegenerative disorders that include amyotrophic lateral sclerosis, multiple sclerosis, Parkinsons disease, and others. The company holds rights to develop and commercialize its NurOwn technology through a licensing agreement with Ramot of Tel Aviv University Ltd. Its NurOwn technology is based on a novel differentiation protocol, which induces differentiation of the bone marrow-derived mesenchymal stem cells into neuron-supporting cells and secreting cells that release various neurotrophic factors, including glial-derived neurotrophic factor, brain-derived neurotrophic factor, vascular endothelial growth factor, and hepatocyte growth factor for the growth, survival, and differentiation of developing neurons. The company was formerly known as Golden Hand Resources Inc. and changed its name to Brainstorm Cell Therapeutics Inc. in November 2004 to reflect its new line of business in the development of novel cell therapies for neurodegenerative diseases. Brainstorm Cell Therapeutics Inc. was founded in 2000 and is headquartered in Hackensack, New Jersey.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Go here to read the rest:
Reviewing Morphic Holding Inc. (MORF)'s and Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI)'s results - MS Wkly

We will be contrasting the differences between PTC Therapeutics Inc. (NASDAQ:PTCT) and Inovio Pharmaceuticals Inc. (NASDAQ:INO) as far as dividends, analyst recommendations, profitability, risk, earnings and valuation, institutional ownership are concerned. The two businesses are rivals in the Biotechnology industry.

Valuation and Earnings

Table 1 shows gross revenue, earnings per share and valuation of the two companies.

Profitability

Table 2 represents PTC Therapeutics Inc. (NASDAQ:PTCT) and Inovio Pharmaceuticals Inc. (NASDAQ:INO)s return on equity, return on assets and net margins.

Volatility and Risk

PTC Therapeutics Inc. is 74.00% more volatile than Standard & Poors 500 because the company has a beta of 1.74. Inovio Pharmaceuticals Inc. has a 2.01 beta and it is 101.00% more volatile than Standard & Poors 500.

Liquidity

PTC Therapeutics Inc.s Current Ratio and Quick Ratio are 3.3 and 3.2 respectively. The Current Ratio and Quick Ratio of its competitor Inovio Pharmaceuticals Inc. are 4.9 and 4.9 respectively. Inovio Pharmaceuticals Inc. therefore has a better chance of paying off short and long-term obligations compared to PTC Therapeutics Inc.

Insider & Institutional Ownership

The shares of both PTC Therapeutics Inc. and Inovio Pharmaceuticals Inc. are owned by institutional investors at 85.61% and 44% respectively. 0.3% are PTC Therapeutics Inc.s share held by insiders. Comparatively, insiders own roughly 2.5% of Inovio Pharmaceuticals Inc.s shares.

Performance

In this table we show the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

For the past year PTC Therapeutics Inc. had bullish trend while Inovio Pharmaceuticals Inc. had bearish trend.

PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of orally administered, small molecule drugs that target post-transcriptional control processes. The companys lead product is Translarna (ataluren), for the treatment of nonsense mutation Duchenne muscular dystrophy in ambulatory patients; and which is in phase III clinical trials to treat cystic fibrosis caused by nonsense mutations. It also develops Translarna, which is in Phase II clinical trials for the treatment of mucopolysaccharidosis type I caused by nonsense mutation, nonsense mutation aniridia, and nonsense mutation Dravet syndrome/CDKL5; and RG7916 that is in Phase I clinical trials to treat spinal muscular atrophy. In addition, the companys product candidate in cancer stem cell program include PTC596, an orally bioavailable and potent small molecule, which has completed phase I clinical trials that targets tumor stem cell populations by reducing the activity and amount of a protein called BMI1. PTC Therapeutics, Inc. has collaborations with F. Hoffman-La Roche Ltd and Hoffman-La Roche Inc., and the Spinal Muscular Atrophy Foundation to develop and commercialize compounds identified under its spinal muscular atrophy sponsored research program; and research collaboration with Massachusetts General Hospital for the treatment of rare genetic disorders resulting from pre-mRNA. The company was founded in 1998 and is headquartered in South Plainfield, New Jersey.

Inovio Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops active DNA immunotherapies and vaccines in combination with proprietary electroporation delivery devices to prevent and treat cancers and infectious diseases. Its SynCon immunotherapy design has the ability to break the immune systems tolerance of cancerous cells; and SynCon product design is also intended to facilitate cross-strain protection against known, as well as new unmatched strains of pathogens, such as influenza. It has completed, current or planned clinical programs of its proprietary SynCon immunotherapies for HPV-caused pre-cancers and cancers, influenza, prostate cancer, breast/lung/pancreatic cancer, hepatitis C virus, hepatitis B virus, HIV, Ebola, Middle East Respiratory Syndrome, and Zika virus. The companys partners and collaborators include MedImmune, LLC, the Wistar Institute, University of Pennsylvania, Defense Advanced Research Projects Agency, GeneOne Life Science, Plumbline Life Sciences, ApolloBio Corporation, Drexel University, the National Institutes of Health, HIV Vaccines Trial Network, National Cancer Institute, Genentech, and U.S. Military HIV Research Program. Inovio Pharmaceuticals, Inc. was founded in 1979 and is headquartered in Plymouth Meeting, Pennsylvania.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

See the article here:
Reviewing PTC Therapeutics Inc. (PTCT)'s and Inovio Pharmaceuticals Inc. (NASDAQ:INO)'s results - MS Wkly

Since Osmotica Pharmaceuticals plc (NASDAQ:OSMT) and VistaGen Therapeutics Inc. (NASDAQ:VTGN) are part of the Biotechnology industry, they are influenced by contrast. The influences particularly affect the risk, analyst recommendations, institutional ownership, profitability, dividends, earnings and valuation of both companies.

Valuation and Earnings

Table 1 shows top-line revenue, earnings per share (EPS) and valuation of the two companies.

Profitability

Table 2 shows the return on equity, net margins and return on assets of the two firms.

Liquidity

The Current Ratio and Quick Ratio of Osmotica Pharmaceuticals plc are 1.7 and 1.4 respectively. Its competitor VistaGen Therapeutics Inc.s Current Ratio is 4.9 and its Quick Ratio is 4.9. VistaGen Therapeutics Inc. can pay off short and long-term obligations better than Osmotica Pharmaceuticals plc.

Institutional & Insider Ownership

Osmotica Pharmaceuticals plc and VistaGen Therapeutics Inc. has shares owned by institutional investors as follows: 50.4% and 20.4%. 4% are Osmotica Pharmaceuticals plcs share owned by insiders. Comparatively, VistaGen Therapeutics Inc. has 0.2% of its share owned by insiders.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

For the past year Osmotica Pharmaceuticals plc was less bearish than VistaGen Therapeutics Inc.

Summary

On 5 of the 9 factors VistaGen Therapeutics Inc. beats Osmotica Pharmaceuticals plc.

Osmotica Pharmaceuticals plc, an integrated biopharmaceutical company, develops, manufactures, and commercializes specialty products that target markets with underserved patient populations. The company's promoted approved products include specialty neurology products, such as M-72 to treat ADHD; Osmolex ER to treat Parkinson's and drug-induced extrapyramidal reactions in adults; Lorzone to treat muscle spasms; and ConZip for pain, as well as women's health products, including Divigel for menopause; and OB Complete, a dietary supplement for prenatal, pregnancy, and postnatal periods. Its non-promoted approved products comprise Methylphenidate ER for ADHD; Venlafaxine ER tablets for major depressive disorder and social anxiety disorder; Hydromorphone ER for pain; Nifedipine ER for hypertension; Sodium Benzoate/Sodium Phenylacetate for hyperammonemia; Oxybutynin ER for overactive bladder; and prescription prenatal vitamins for nutritional requirements during pregnancy. The company's products under development include Ontinua ER, which is in Phase III clinical trials to treat multiple sclerosis spasticity, and Phase I clinical trials to treat opioid and alcohol use disorders; RVL-1201, which is in Phase III clinical trials to treat Blepharoptosis; and Osmodex and other ANDAs for various indications. Osmotica Pharmaceuticals plc is based in Bridgewater, New Jersey.

VistaGen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing medicines for depression and other central nervous system (CNS) disorders. The company's lead product candidate is AV-101, which is in Phase II development stage, an adjunctive treatment used for major depressive disorder. It also focuses on potential commercial applications of its human pluripotent stem cell (hPSC) technology platform to discover, rescue, develop, and commercialize new chemical entities (NCEs) for CNS and other diseases; and regenerative medicine involving hPSC-derived blood, cartilage, heart, and liver cells. In addition, the company develops CardioSafe 3D, an in vitro cardiac bioassay system for predicting human heart toxicity of small molecule NCEs. VistaGen Therapeutics, Inc. has licensing, sublicensing, and collaboration agreements with BlueRock Therapeutics, LP; U.S. National Institutes of Health; Cato Research Ltd.; and University Health Network. The company was founded in 1998 and is headquartered in South San Francisco, California.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Read the original:
Comparing of Osmotica Pharmaceuticals plc (OSMT) and VistaGen Therapeutics Inc. (NASDAQ:VTGN) - MS Wkly

This is a contrast between PTC Therapeutics Inc. (NASDAQ:PTCT) and MacroGenics Inc. (NASDAQ:MGNX) based on their institutional ownership, earnings and valuation, profitability, risk, dividends, analyst recommendations. The two companies are Biotechnology and they also compete with each other.

Valuation & Earnings

Demonstrates PTC Therapeutics Inc. and MacroGenics Inc. earnings per share (EPS), top-line revenue and valuation.

Profitability

Table 2 shows the return on assets, net margins and return on equity of the two firms.

Volatility & Risk

PTC Therapeutics Inc.s 1.74 beta indicates that its volatility is 74.00% more volatile than that of Standard & Poors 500. MacroGenics Inc. has a 2.3 beta and it is 130.00% more volatile than Standard & Poors 500.

Liquidity

PTC Therapeutics Inc.s Current Ratio is 3.3 while its Quick Ratio is 3.2. On the competitive side is, MacroGenics Inc. which has a 6.5 Current Ratio and a 6.5 Quick Ratio. MacroGenics Inc. is better positioned to pay off short and long-term obligations compared to PTC Therapeutics Inc.

Analyst Recommendations

PTC Therapeutics Inc. and MacroGenics Inc. Recommendations and Ratings are available in the next table.

PTC Therapeutics Inc. has a 21.85% upside potential and a consensus price target of $43. Competitively the consensus price target of MacroGenics Inc. is $27, which is potential 137.26% upside. Based on the results shown earlier, MacroGenics Inc. is looking more favorable than PTC Therapeutics Inc., analysts view.

Institutional and Insider Ownership

PTC Therapeutics Inc. and MacroGenics Inc. has shares owned by institutional investors as follows: 85.61% and 95.8%. About 0.3% of PTC Therapeutics Inc.s share are owned by insiders. Comparatively, 0.1% are MacroGenics Inc.s share owned by insiders.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

For the past year PTC Therapeutics Inc. has stronger performance than MacroGenics Inc.

Summary

On 7 of the 12 factors PTC Therapeutics Inc. beats MacroGenics Inc.

PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of orally administered, small molecule drugs that target post-transcriptional control processes. The companys lead product is Translarna (ataluren), for the treatment of nonsense mutation Duchenne muscular dystrophy in ambulatory patients; and which is in phase III clinical trials to treat cystic fibrosis caused by nonsense mutations. It also develops Translarna, which is in Phase II clinical trials for the treatment of mucopolysaccharidosis type I caused by nonsense mutation, nonsense mutation aniridia, and nonsense mutation Dravet syndrome/CDKL5; and RG7916 that is in Phase I clinical trials to treat spinal muscular atrophy. In addition, the companys product candidate in cancer stem cell program include PTC596, an orally bioavailable and potent small molecule, which has completed phase I clinical trials that targets tumor stem cell populations by reducing the activity and amount of a protein called BMI1. PTC Therapeutics, Inc. has collaborations with F. Hoffman-La Roche Ltd and Hoffman-La Roche Inc., and the Spinal Muscular Atrophy Foundation to develop and commercialize compounds identified under its spinal muscular atrophy sponsored research program; and research collaboration with Massachusetts General Hospital for the treatment of rare genetic disorders resulting from pre-mRNA. The company was founded in 1998 and is headquartered in South Plainfield, New Jersey.

MacroGenics, Inc., a biopharmaceutical company, focuses on the discovery and development of antibody-based therapeutics for the treatment of cancer primarily by modulating the human immune system, as well as various autoimmune disorders and infectious diseases in the United States. The companys advanced clinical product candidate is Margetuximab, a monoclonal antibody, which is in Phase III clinical trial that targets human epidermal growth factor receptor 2-expressing tumors, such as various breast and gastroesophageal cancers. It also develops Enoblituzumab, a monoclonal antibody, which is in Phase 1 clinical trial as monotherapy in multiple solid tumor types, as well as in combination therapy with either an anti-PD-1 antibody or an anti-CTLA-4 antibody; Flotetuzumab, a DART molecule that targets CD123 and CD3; MGD007, a DART molecule, which targets glycoprotein A33 and CD3; Duvortuxizumab, a DART molecule that targets both CD19 and CD3; MGD009, a molecule in its B7-H3 franchise; MGA012, a monoclonal antibody, which targets PD-1; MGD013, a DART molecule that enables the co-blockade with a single recombinant agent of two immune checkpoint molecules; and MGC018, a B7-H3 antibody-drug conjugate. In addition, the companys products include MGD010, a DART molecule designed to address limitations of existing B cell-targeted therapies by binding to the CD32B and CD79B proteins found on human B cells; Teplizumab, an anti-CD3 monoclonal antibody to treat type 1 diabetes; and MGD014, a DART molecule that targets human immunodeficiency virus, or HIV-infected cells, and CD3-expressing T cells. It has collaboration and license agreements with Janssen Biotech, Inc.; Les Laboratoires Servier and Institut de Recherches Servier; Boehringer Ingelheim GmbH; Pfizer, Inc.; and Green Cross Corp. MacroGenics, Inc. was founded in 2000 and is headquartered in Rockville, Maryland.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Read this article:
PTC Therapeutics Inc. (PTCT) and MacroGenics Inc. (NASDAQ:MGNX) Comparing side by side - MS Wkly